<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Myeloid Malignancies</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\(', '\)']],
            displayMath: [['$$', '$$'], ['\[', '\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hematology-hemostasis-coagulation.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 66.67%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 4 of 6</span> <!-- Update text -->
                    </div>
                    <a href="hematology-lymphoid-malignancies.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Hematologic Malignancies</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: malignancies-overview -->
                <section id="malignancies-overview" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">OVERVIEW</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Myeloid</h3>
                        <p>clonal stem cell neoplasms</p>
                        <ol type="i">
                            <li>acute myeloid leukemia (clonal proliferation of immature cells)</li>
                            <li>myeloproliferative disorders (proliferation of mature cells)
                                <ul>
                                    <li>polycythemia rubra vera</li>
                                    <li>chronic granulocytic (myelogenous) leukemia</li>
                                    <li>idiopathic myelofibrosis</li>
                                    <li>essential thrombocythemia</li>
                                </ul>
                            </li>
                            <li>myelodysplastic syndromes (defective differentiation)</li>
                        </ol>

                        <h3 class="subsection-heading">Lymphoid</h3>
                        <p>all cells arise from a single abnormal lymphoid precursor (B or T)</p>
                        <ol type="i">
                            <li>acute lymphoblastic leukemia (arise from stem cell)</li>
                            <li>lymphomas (arise from maturing lymphoid cell)
                                <ul>
                                    <li>Hodgkin's lymphoma</li>
                                    <li>non-Hodgkin's lymphoma</li>
                                </ul>
                            </li>
                            <li>malignant clonal proliferation of B cells
                                <ul>
                                    <li>chronic lymphocytic leukemia</li>
                                    <li>plasma cell dyscrasias</li>
                                    <li>light chain disease</li>
                                    <li>monoclonal gammopathy of unknown significance</li>
                                    <li>macroglobulinemia of Waldenstrom</li>
                                    <li>macroglobulinemia-hyperviscosity syndrome</li>
                                </ul>
                            </li>
                        </ol>
                    </div>
                </section>
                <!-- END: malignancies-overview -->

                <!-- START: myeloid-malignancies -->
                <section id="myeloid-malignancies" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">MYELOID MALIGNANCIES</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">ACUTE MYELOID LEUKEMIA (AML)</h3>
                        <ul>
                            <li>failure of myeloid cell to differentiate beyond blast stage</li>
                            <li>clonal proliferation of immature hematopoietic cells</li>
                            <li>incidence increases with age</li>
                            <li>associated with exposure to benzene, radiation and alkylating agents</li>
                        </ul>
                        <h4>Pathophysiology</h4>
                        <p>uncontrolled growth of blasts in marrow leads to</p>
                        <ul>
                            <li>suppression of normal hematopoietic cells</li>
                            <li>appearance of blasts in peripheral blood</li>
                            <li>accumulation of blasts in other sites</li>
                            <li>metabolic consequences of a large tumour mass</li>
                        </ul>
                        <p>chronic myeloproliferative disorders and myelodysplastic syndromes can transform into AML</p>
                        <h4>Clinical Features of AML</h4>
                        <p><strong>decrease in normal hematopoiesis</strong></p>
                        <ul>
                            <li>anemia
                                <ul><li>pallor, weakness, fatigue, dyspnea on exertion</li></ul>
                            </li>
                            <li>thrombocytopenia
                                <ul>
                                    <li>purpura</li>
                                    <li>mucosal bleeding</li>
                                    <li>associated with DIC (promyelocytic leukemia- a type of AML)</li>
                                </ul>
                            </li>
                            <li>neutropenia → infections
                                <ul>
                                    <li>septicemia</li>
                                    <li>pneumonitis</li>
                                    <li>skin and mucosal infections</li>
                                </ul>
                            </li>
                        </ul>
                        <p><strong>accumulation of blast cells in marrow</strong></p>
                        <ul>
                            <li>skeletal pain</li>
                            <li>bony tenderness, especially sternum</li>
                        </ul>
                        <p><strong>accumulation of blast cells at other sites</strong></p>
                        <ul>
                            <li>lymphadenopathy</li>
                            <li>hepatosplenomegaly</li>
                            <li>gums</li>
                            <li>skin - leukemia cutis</li>
                            <li>CNS - N/V, H/A, papilledema +/- hemorrhage</li>
                            <li>gonads</li>
                            <li>eyes - Roth spots (oval retinal hemorrhages surrounding pale spot), blurred vision, diplopia</li>
                        </ul>
                        <p><strong>metabolic effects - aggravated by treatment</strong></p>
                        <ul>
                            <li>increase in uric acid → uric acid nephropathy</li>
                            <li>release of phosphates → decrease in Ca<sup>2+</sup> and Mg<sup>2+</sup></li>
                            <li>release of pro-coagulants -> DIC</li>
                        </ul>
                        <h4>Diagnosis</h4>
                        <ul>
                            <li><strong>peripheral blood film (see Colour Atlas H11)</strong>
                                <ul>
                                    <li>decreased hemoglobin (usually normocytic, normochromic anemia) and platelets</li>
                                    <li>variable leukocyte count</li>
                                    <li>decrease in normal granulocytes</li>
                                    <li>presence of blast cells (Auer Rods) - azurophilic granules within lysosomes</li>
                                </ul>
                            </li>
                            <li><strong>bone marrow</strong>
                                <ul>
                                    <li>usually hypercellular</li>
                                    <li>increased blast cells - > 30% leukemic blasts for definitive diagnosis (normal < 5%)</li>
                                    <li>decrease in normal erythropoiesis, myelopoiesis, megakaryocytes</li>
                                </ul>
                            </li>
                            <li>cytogenetics and molecular analysis</li>
                            <li>INR (PT), PTT, FDP, fibrinogen in case of DIC</li>
                            <li>increased uric acid, LDH and LFTs</li>
                            <li>decreased Ca<sup>2+</sup></li>
                            <li>baseline urea and creatinine</li>
                            <li>chest x-ray to r/o mediastinal compression and infection</li>
                        </ul>
                        <h4>Management of AML</h4>
                        <ul>
                            <li>cure - defined as survival that parallels age-matched population</li>
                            <li>first step is complete remission- defined as normal peripheral blood smear, normal bone marrow with < 5% blasts, and normal clinical state</li>
                            <li>leukemia will recur after complete remission if no further treatment given</li>
                            <li><strong>aims of treatment</strong>
                                <ul>
                                    <li>eliminate abnormal clone - cytotoxic therapy
                                        <ol>
                                            <li>Induction</li>
                                            <li>Consolidation or BMT</li>
                                        </ol>
                                    </li>
                                    <li>repopulation of marrow with normal hemopoietic cells
                                        <ul><li>consider acceleration with hematopoetic growth factors e.g. G-CSF, GM-CSF if increased incidence of severe infection</li></ul>
                                    </li>
                                </ul>
                            </li>
                            <li><strong>supportive care</strong>
                                <ul>
                                    <li>prophylaxis against infection via regular C&S of urine, feces, sputum, oropharynx, catheter sites, perianal area</li>
                                    <li>antibiotics if fever with C&S of all orifices and chest x-ray</li>
                                    <li>platelet and RBC transfusions - CMV negative products</li>
                                    <li>prevention and treatment of metabolic abnormalities</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Prognosis</h4>
                        <ul>
                            <li>achievement of first remission
                                <ul>
                                    <li>70-80% if 60 years old, 50% if > 60 years old</li>
                                    <li>median survival 12-24 months</li>
                                    <li>5 year survival 40%</li>
                                </ul>
                            </li>
                            <li>statistics may be improved by BMT - 50-60% cure rate</li>
                        </ul>
                    </div>
                </section>
                <!-- END: myeloid-malignancies -->

                <!-- START: chronic-myeloproliferative -->
                <section id="chronic-myeloproliferative" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">CHRONIC MYELOPROLIFERATIVE DISORDERS</span>
                    </h2>
                    <div class="content-card">
                        <p>clonal myeloid stem cell abnormalities leading to qualitative and quantitative changes to erythroid, myeloid, and platelet cells may develop marrow fibrosis with time all disorders may progress to acute myelogenous leukemia mainly middle-aged and older patients</p>
                        <h3 class="subsection-heading">COMMON FEATURES</h3>
                        <p><strong>increased</strong></p>
                        <ul>
                            <li>uric acid</li>
                            <li>LDH</li>
                            <li>serum B12</li>
                            <li>transcobalamin I</li>
                            <li>eosinophils</li>
                            <li>basophils</li>
                            <li>blood histamine (from basophils)</li>
                        </ul>
                        <p>pruritus</p>
                        <p>bruising</p>
                        <p>thrombosis</p>
                        <p>peptic ulcer disease (histamine increases acid secretion)</p>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 12. Chronic Myeloproliferative Disorders</caption>
                                <thead>
                                    <tr><th></th><th>PRV</th><th>CGL (CML)</th><th>IMF</th><th>ET</th></tr>
                                </thead>
                                <tbody>
                                    <tr><td>HCT</td><td>↑↑</td><td>↓/N</td><td>↓</td><td>N</td></tr>
                                    <tr><td>WBC</td><td>↑</td><td>↑↑</td><td>↑/↓</td><td>N</td></tr>
                                    <tr><td>PLT</td><td>↑</td><td>↑/↓</td><td>↑/↓</td><td>↑↑↑</td></tr>
                                    <tr><td>LAP</td><td>↑↑</td><td>↓</td><td>↑/N</td><td>↑/N</td></tr>
                                    <tr><td>marrow fibrosis</td><td>±</td><td>±</td><td>+++</td><td>±</td></tr>
                                    <tr><td>splenomegaly</td><td>+</td><td>+++</td><td>+++</td><td>+</td></tr>
                                    <tr><td>hepatomegaly</td><td>-</td><td>+</td><td>++</td><td>-</td></tr>
                                    <tr>
                                        <td colspan="5" style="text-align:center;">
                                            PRV = polycythemia rubra vera &nbsp;&nbsp; CGL = chronic granulocytic leukemia<br>
                                            IMF = idiopathic myelofibrosis &nbsp;&nbsp; ET = essential thrombocythemia
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3 class="subsection-heading">POLYCYTHEMIA RUBRA VERA (PRV)</h3>
                        <p>autonomous overproduction of erythroid cells</p>
                        <h4>Clinical Features</h4>
                        <ul>
                            <li><strong>secondary to high red cell mass and hyperviscosity</strong>
                                <ul>
                                    <li>headache, dizziness, tinnitus</li>
                                    <li>congestive heart failure</li>
                                    <li>thrombosis</li>
                                </ul>
                            </li>
                            <li><strong>secondary to platelet abnormalities</strong>
                                <ul>
                                    <li>cerebrovascular accident</li>
                                    <li>myocardial infarction</li>
                                    <li>phlebitis</li>
                                    <li>bleeding, bruising</li>
                                </ul>
                            </li>
                            <li><strong>secondary to high blood histamine (from basophils)</strong>
                                <ul>
                                    <li>pruritus, especially post-bath or shower</li>
                                    <li>peptic ulcer</li>
                                </ul>
                            </li>
                            <li><strong>secondary to high cell turnover</strong>
                                <ul><li>gout (due to hyperuricemia)</li></ul>
                            </li>
                        </ul>
                        <h4>Management</h4>
                        <ul>
                            <li>phlebotomy
                                <ul><li>if symptoms are due to erythrocytosis alone and platelet count normal or only slightly increased</li></ul>
                            </li>
                            <li>alkylating agents
                                <ul><li>if symptoms systemic or secondary to splenic enlargement</li></ul>
                            </li>
                            <li>antihistamines</li>
                            <li>allopurinol</li>
                            <li><sup>32</sup>P</li>
                        </ul>
                        <h4>Complications</h4>
                        <ul>
                            <li>vascular complications (thrombosis, hemorrhage)</li>
                            <li>myeloid metaplasia</li>
                            <li>acute leukemia</li>
                        </ul>
                        <h4>Causes of Secondary Polycythemia</h4>
                        <ul>
                            <li>spurious (decrease in plasma volume)</li>
                            <li><strong>poor tissue oxygenation</strong>
                                <ul>
                                    <li>high altitude</li>
                                    <li>cyanotic congenital heart disease or pulmonary disease</li>
                                    <li>hemoglobinopathies with increased O<sub>2</sub> affinity</li>
                                    <li>carbon monoxide poisoning</li>
                                </ul>
                            </li>
                            <li><strong>local renal hypoxia</strong>
                                <ul>
                                    <li>renal artery stenosis</li>
                                    <li>renal cysts</li>
                                </ul>
                            </li>
                            <li><strong>ectopic production of erythropoietin</strong>
                                <ul>
                                    <li>uterine leiomyoma</li>
                                    <li>cerebellar hemangioma</li>
                                    <li>hepatocellular cancer</li>
                                    <li>pheochromocytoma</li>
                                    <li>renal cell cancer</li>
                                </ul>
                            </li>
                        </ul>

                        <h3 class="subsection-heading">CHRONIC GRANULOCYTIC (MYELOGENOUS) LEUKEMIA (CML)</h3>
                        <p>overproduction of myeloid cells, erythoid cells and platelets in peripheral blood marked myeloid hyperplasia in bone marrow</p>
                        <h4>Clinical Features</h4>
                        <ul>
                            <li>disorder of middle age</li>
                            <li>40% asymptomatic</li>
                            <li><strong>secondary to splenic involvement</strong>
                                <ul>
                                    <li>splenomegaly (most common physical finding)</li>
                                    <li>shoulder tip pain due to splenic infarction</li>
                                </ul>
                            </li>
                            <li><strong>secondary to high blood histamine</strong>
                                <ul><li>pruritus, peptic ulcer</li></ul>
                            </li>
                            <li><strong>secondary to rapid cell turnover</strong>
                                <ul><li>fever, weight loss</li></ul>
                            </li>
                            <li><strong>secondary to anemia</strong>
                                <ul><li>symptoms of anemia - most commonly fatigue</li></ul>
                            </li>
                            <li><strong>secondary to gross elevation of the WBC (rare)</strong>
                                <ul>
                                    <li>encephalopathy</li>
                                    <li>priapism</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Diagnostic Features</h4>
                        <ul>
                            <li><strong>Philadelphia (Ph1) chromosome</strong>
                                <ul>
                                    <li>translocation between chromosomes 9 and 22</li>
                                    <li>the c-abl proto-oncogene is translocated from chromosome 9 to "breakpoint cluster region" (bcr) of chromosome 22 to produce bcr-c-abl fusion gene, an active tyrosine kinase</li>
                                    <li>detection of this fusion gene is a diagnostic test for CML (present in over 90% of patients)</li>
                                </ul>
                            </li>
                            <li><strong>leukocyte alkaline phosphatase (LAP)</strong>
                                <ul>
                                    <li>normal constituent of secondary neutrophil granules</li>
                                    <li>low or absent (normal or increased in other chronic myeloproliferative diseases and reactive states)</li>
                                </ul>
                            </li>
                            <li><strong>peripheral blood film (see Colour Atlas H10)</strong>
                                <ul>
                                    <li>leukocytosis with early myeloid precursors</li>
                                    <li>eosinophils and basophils may be increased</li>
                                    <li>hypogranular basophils</li>
                                </ul>
                            </li>
                            <li><strong>bone marrow</strong>
                                <ul><li>myeloid hyperplasia with a left shift, increased megakaryocytes and increased reticulin or fibrosis</li></ul>
                            </li>
                        </ul>
                        <h4>Course/Outcomes</h4>
                        <ul>
                            <li><strong>chronic phase</strong>
                                <ul>
                                    <li>normal bone marrow function</li>
                                    <li>white blood cells differentiate and function normally</li>
                                </ul>
                            </li>
                            <li><strong>accelerated phase</strong>
                                <ul>
                                    <li>fever</li>
                                    <li>marked increase in basophils</li>
                                    <li>increased extramedullary hematopoiesis (unusual sites)</li>
                                    <li>transformation → disease similar to idiopathic myelofibrosis</li>
                                    <li>pancytopenia secondary to marrow aplasia</li>
                                </ul>
                            </li>
                             <li><strong>acute phase (blast transformation)</strong>
                                <ul>
                                    <li>2/3 develop a picture similar to AML
                                        <ul><li>unresponsive to remission induction</li></ul>
                                    </li>
                                    <li>1/3 develop a picture similar to ALL
                                        <ul><li>remission induction (return to chronic phase) achievable</li></ul>
                                    </li>
                                    <li>sepsis</li>
                                    <li>bleeding</li>
                                    <li>thrombosis</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Management</h4>
                        <ul>
                            <li><strong>symptomatic</strong>
                                <ul><li>allopurinol and antihistamines</li></ul>
                            </li>
                            <li><strong>chronic phase</strong>
                                <ul>
                                    <li>hydroxyurea or occasionally busulfan</li>
                                    <li>interferon</li>
                                    <li>STI 571</li>
                                </ul>
                            </li>
                            <li>only curative treatment is bone marrow transplantation</li>
                        </ul>

                        <h3 class="subsection-heading">IDIOPATHIC MYELOFIBROSIS (IMF)</h3>
                        <p>marrow replaced by fibrosis - abnormal megakaryocytes stimulate collagen deposition</p>
                        <h4>Clinical Features</h4>
                        <p>same as CML except no priapism or encephalopathy</p>
                        <h4>Diagnostic Features</h4>
                        <ul>
                            <li>significant hemolysis due to hypersplenism and red cell fragmentation</li>
                            <li><strong>peripheral blood film (see Colour Atlas H16)</strong>
                                <ul>
                                    <li>tear drop cells</li>
                                    <li>red cell and megakaryocyte fragments</li>
                                    <li>increased polychromasia</li>
                                    <li>nucleated RBCs and poikilocytes</li>
                                    <li>giant abnormal platelets due to early release from marrow</li>
                                    <li>leukoerythroblastic changes i.e. due to the space occupying lesions in the bone marrow, a variable number of erythroid and myeloid cells are released into the circulation</li>
                                </ul>
                            </li>
                            <li><strong>bone marrow</strong>
                                <ul>
                                    <li>replaced with fibrosis, difficult to aspirate</li>
                                    <li>megakaryocytes normal or increased</li>
                                </ul>
                            </li>
                        </ul>
                        <h4>Management</h4>
                        <ul>
                            <li>transfusion</li>
                            <li>erythropoietin</li>
                            <li>androgens</li>
                            <li>allopurinol and antihistamines</li>
                            <li>folic acid if stores depleted</li>
                            <li>desferoxamine for iron overload (iron and aluminum chelator)</li>
                            <li>hydroxyurea in extremely small doses</li>
                            <li>splenectomy in highly selected cases</li>
                            <li>bone marrow transplant</li>
                        </ul>
                        <h4>Complications</h4>
                        <ul>
                            <li>refractory anemia</li>
                            <li>pancytopenia</li>
                            <li>transformation to AML</li>
                            <li>thrombosis and bleeding</li>
                        </ul>

                        <h3 class="subsection-heading">ESSENTIAL THROMBOCYTHEMIA</h3>
                        <p>overproduction of platelets in absence of recognizable stimulus invariably above 400,000/mL</p>
                        <h4>Clinical Features</h4>
                        <ul>
                            <li>asymptomatic most common</li>
                            <li>bleeding - although plentiful, platelets are not working</li>
                            <li>thrombosis</li>
                            <li>symptoms 2° to splenic enlargement, high blood histamine, and rapid cell turnover - as per CML and IMF</li>
                        </ul>
                        <h4>Laboratory Features</h4>
                        <ul>
                            <li>defect in platelet function may be present</li>
                            <li>elevation of phosphatase and potassium in plasma sample due to release of cytoplasmic content from aggregation of platelets</li>
                        </ul>
                        <h4>Diagnosis</h4>
                        <p>exclude other myeloproliferative diseases and 2° thrombocythemia</p>
                        <h4>Management</h4>
                        <ul>
                            <li>hydroxyurea</li>
                            <li><sup>32</sup>P</li>
                            <li>plateletpheresis</li>
                            <li>avoid splenectomy as spleen is removing unwanted platelets</li>
                        </ul>
                        <h4>Complications</h4>
                        <ul>
                            <li>bleeding</li>
                            <li>thrombosis</li>
                            <li>leukemic transformation</li>
                            <li>transformation to myelofibrosis</li>
                        </ul>
                        <aside class="callout note" role="note">
                            <h4 class="callout-title"><span class="callout-icon"> </span>Clinical Pearl</h4>
                            <p>There is an asymptomatic "benign" form of essential thrombocythemia with a stable or slowly rising platelet count; treatment includes observation, ASA, sulfinpyrazone or dipyridamole.</p>
                        </aside>
                        <h4>Causes of Secondary Thrombocythemia</h4>
                        <ul>
                            <li>infection</li>
                            <li>inflammation (IBD, arthritis)</li>
                            <li>malignancy</li>
                            <li>hemorrhage</li>
                            <li>Fe deficiency</li>
                            <li>hemolytic anemia</li>
                            <li>post splenectomy</li>
                            <li>post chemotherapy</li>
                        </ul>
                    </div>
                </section>
                <!-- END: chronic-myeloproliferative -->

                <!-- START: myelodysplastic-syndromes -->
                <section id="myelodysplastic-syndromes" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">MYELODYSPLASTIC SYNDROMES</span>
                    </h2>
                    <div class="content-card">
                        <p>set of clonal disorders characterized by one or more cytopenias with anemia present ineffective hematopoiesis despite presence of adequate numbers of progenitor cells (bone marrow is usually hyper-cellular) considered preleukemic: 30-70% develop AML most common in elderly, post-chemotherapy, benzene or radiation exposure insidious onset</p>
                        <p><strong>clinical presentation</strong></p>
                        <ul>
                            <li>fatigue, weakness, pallor, infections, bruising and rarely weight loss, fever, and hepatosplenomegaly</li>
                        </ul>
                        <p><strong>diagnostic triad</strong></p>
                        <ol>
                            <li>anemia ± thrombocytopenia ± neutropenia</li>
                            <li>bone marrow hypercellular or normocellular</li>
                            <li>dysmyelopoiesis in bone marrow precursors</li>
                        </ol>
                        <p><strong>hematological changes</strong></p>
                        <ul>
                            <li>RBC: variable morphology with decreased reticulocyte count</li>
                            <li>WBC: decrease in granulocytes and abnormal function</li>
                            <li>platelet: either too large or too small and thrombocytopenia</li>
                        </ul>
                        <h3 class="subsection-heading">FAB Classification</h3>
                        <ul>
                            <li>refractory anemia (RA)</li>
                            <li>refractory anemia with ring sideroblasts (RARS)</li>
                            <li>refractory anemia with excess blasts (RAEB)</li>
                            <li>refractory anemia with excess blasts in transformation (RAEB-T)</li>
                            <li>chronic myelomonocytic leukemia (CMML)</li>
                        </ul>
                        <h3 class="subsection-heading">Management</h3>
                        <ul>
                            <li>symptomatic: transfusion, antibiotics</li>
                            <li>hematopoietic growth factors (G-CSF, GM-CSF) may decrease risk of infection</li>
                            <li>erythropoietics</li>
                            <li>AML induction chemotherapy: 50-60% remission, 90% relapse</li>
                            <li>bone marrow transplant may be curative</li>
                        </ul>
                    </div>
                </section>
                <!-- END: myelodysplastic-syndromes -->

            </main>

            <!-- Bottom Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="hematology-hemostasis-coagulation.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 66.67%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 4 of 6</span> <!-- Update text -->
                    </div>
                    <a href="hematology-lymphoid-malignancies.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>